Introduction
============

Colorectal cancer (CRC) is one of the most common types of gastrointestinal cancer. Almost two million new cases of CRC are diagnosed every year, making CRC the third most common cancer and the fourth most common cancer-associated cause of mortality in the world ([@b1-ol-0-0-8070]--[@b3-ol-0-0-8070]). The risk of CRC increases in certain populations and is associated with risk factors including: Hereditary nonpolyposis CRC; inflammatory bowel disease; a family history of CRC; being of African American descent ([@b4-ol-0-0-8070]--[@b6-ol-0-0-8070]). Patients with CRC are typically asymptomatic and therefore it is difficult to the disease diagnose until advanced stages, where the disease becomes incurable. Early diagnosis and therapy is able to decrease the risk of CRC in this asymptomatic population; however, early diagnosis of CRC remains a challenge in clinical practice. Hence, identification of novel non-invasive diagnostic methods for early tumor detection in CRC is required ([@b7-ol-0-0-8070],[@b8-ol-0-0-8070]).

The tumor protein (TP)53 gene is the most widely used tumor biomarker in detecting a potential tumor as p53 mutations are the most commonly observed mutations in different types of cancer. Furthermore, the majority of anti-p53 autoantibodies are produced in response to p53 mutation ([@b9-ol-0-0-8070]). In healthy cells a p53 nuclear phosphoprotein is expressed as a protein product of the p53 gene. In contrast with p53 protein, anti-p53 antibodies are rarely detected in the serum of healthy controls ([@b10-ol-0-0-8070]). Mutated p53 leads to the accumulation of nonfunctional protein due to the increased stability and increased half-life (several h) compared with wild type p53 (20 min) ([@b10-ol-0-0-8070]). The accumulated protein acts as an antigen, leading to the subsequent development of anti-p53 antibodies, which are detectable within tissues and blood ([@b10-ol-0-0-8070],[@b11-ol-0-0-8070]). Due to the expanding field of molecular biotechnology, numerous studies on the potential diagnostic value of s-p53 antibody in CRC have been conducted ([@b11-ol-0-0-8070],[@b12-ol-0-0-8070]). The primary aim of the present meta-analysis was to determine whether the s-p53 antibody may be a potential biomarker for the diagnosis of CRC, and confirmed the accuracy of s-p53 antibody for CRC diagnosis.

Materials and methods
=====================

### Systematic review strategies

The present study systematically searched the following databases; Cochrane Library (<http://www.cochranelibrary.com/>), PubMed (<https://www.ncbi.nlm.nih.gov/pubmed>) and EmBase (<https://www.elsevier.com/solutions/embase-biomedical-research>) accessed on and prior to 31 July 2016. Articles investigating s-p53 antibodies being used for the detection of CRC were taken into account in the present study. The following combined search terms were used: 'Colorectal cancer', 'colorectal carcinoma', 'blood OR serum', 'seropositive OR serum antibody' and 'p53 OR tp53'. PubMed was used to identify associated articles, which were searched manually for associated functions and references ([@b11-ol-0-0-8070]). The study was conducted according to the meta-analysis of observational studies in epidemiology (MOOSE) guidelines ([@b12-ol-0-0-8070],[@b13-ol-0-0-8070]) for systemic reviews and meta-analysis was conducted using PRISMA.

### Inclusion criteria

All articles were evaluated carefully and eligible articles were included if they met the following criteria: i) Studies investigating the diagnostic value of serum (s)-p53 antibody in CRC; ii) articles that diagnosed CRC using the established gold standard (pathological examination of biopsies) and also tested patient serum for the detection of anti-p53 prior to any treatment and used controls without any other cancer; iii) the results of the included articles on diagnostic accuracy were able to be summarized in a 2×2 table.

### Exclusion criteria

The exclusion criteria were as follows: i) If the same author reported results of patients in several publications, only the most relevant one was selected; ii) if available data for analysis was not complete, the study was excluded; iii) all systematic reviews, meta-analyses, case reports and editorials were excluded.

### Data extraction, data synthesis and quality assessment

All articles that were included in the present study were assessed by two different authors, any disagreements between the two authors were resolved by discussion. All the included studies were assessed using the quality assessment for studies of diagnostic accuracy (QUADAS) guidelines ([@b14-ol-0-0-8070]). The Cochrane Collaboration Methods group on screening and diagnostic tests recommended the 11 items of QUADAS. A QUADAS score of ≥7 was considered as good quality and score of \<7 was considered as suboptimal quality. The following data were extracted from the included studies: First author\'s name, year of publication, country of publication, golden criteria of diagnosis, threshold value(s), number of TP (true positive), FP (false positive), FN (false negative), TN (true negative) diagnoses, diagnosis time (the period of time between admission to hospital and diagnosis), stage of tumor (TNM; Japanese classification of colorectal carcinoma, 8th Edition) ([@b15-ol-0-0-8070]) and research methods. To avoid transcriptional errors all data were reviewed twice.

### Statistical analysis

Meta DiSc statistical software (version 1.4; Universidad Complutense, Madrid, Spain) and STATA (version 14.0, Stata Corporation, College Station, TX, USA) were used to analyze the extracted data. The present study adopted standard methods previously recommended for the meta-analysis of diagnostic test evaluations ([@b16-ol-0-0-8070]). The sensitivity, specificity, positive and negative likelihood ratio (PLR and NLR), and 95% confidence intervals (CIs) were calculated with a random effects model according to the Mantel-Haensed method, as previously described ([@b17-ol-0-0-8070]). The diagnostic odds ratio (DOR) was determined using Moses\' constant of linear method and was used to measure the accuracy, which indicates the change in diagnostic performance of the test under study per unit increase in the covariant ([@b18-ol-0-0-8070]). Summary receiver operating characteristic curves (SROC) were used to summarize overall test performance, and the area under the curve (AUC) was calculated. Additionally, the issue associated of sensitivities and specificities of 100% were solved by the default method of adding 0.5 to all cells within the diagnostic 2×2 table ([@b16-ol-0-0-8070],[@b19-ol-0-0-8070]).

The χ^2^ test was applied to detect heterogeneity in the included studies. Inter-study heterogeneity was assessed using the I^2^ test according to the following formula: I^2^=100% × (Cochran Q-degrees of freedom)/Cochran Q ([@b20-ol-0-0-8070]). Meta regression was conducted to detect the heterogeneity between studies. In order to detect cut-off threshold effects, Spearman\'s correlation coefficient was used to evaluate the association between sensitivity and specificity. A scatter plot of the inverse square root of the effective sample size (1/ESS1/2) vs. the diagnostic log odds ratio (lnDOR) was used to visually assess the publication bias is, and should demonstrate a symmetrical funnel shape ([@b21-ol-0-0-8070]).

Results
=======

### Literature search

A total of 206 abstracts and titles were identified following all search strategies as described in [Fig. 1](#f1-ol-0-0-8070){ref-type="fig"}. A total of 136 records were retained in the present study following rejection of replication errors in the included records. In total, 94 articles were excluded, as they did not meet the aforementioned inclusion criteria on the basis of the titles and abstracts. Of the remaining 42 studies, 18 additional articles were excluded due to the lack of a study control, 13 studies were excluded from the meta-analysis due to the lack of s-p53 detection in serum. The final 11 articles included in the present study m*et al*l inclusion criteria and were of good quality ([Tables I](#tI-ol-0-0-8070){ref-type="table"} and [II](#tII-ol-0-0-8070){ref-type="table"}).

### Characteristics of included research

A total of 11 clinical trials presenting the diagnostic value of s-p53 antibody for CRC diagnosis were investigated in the present study, demonstrating different characteristics. For example, studies included in the meta-analyses were conducted in different countries; 6 studies were conducted in Japan ([@b22-ol-0-0-8070]--[@b27-ol-0-0-8070]), 1 was conducted in the USA ([@b28-ol-0-0-8070]), 1 was conducted in Germany ([@b29-ol-0-0-8070]), 1 was conducted in France ([@b30-ol-0-0-8070]) and 2 were conducted in China ([@b31-ol-0-0-8070],[@b32-ol-0-0-8070]). The year of publication ranged between 1997 and 2011. All 11 studies were retrospective; however, 4 studies did not provide TNM stage data ([@b22-ol-0-0-8070],[@b23-ol-0-0-8070],[@b25-ol-0-0-8070],[@b27-ol-0-0-8070]). In total, 10 studies included health volunteers as a control and 1 used patients with benign disease as the control ([@b32-ol-0-0-8070]).

### Threshold effect

Computation of the Spearman correction coefficient for the logit of sensitivity and logit of 1-specificity of s-p53 antibody calculated by metadisc was 0.518 (P=0.102) (data not shown), indicating that there was no threshold effect and positive correlations were not statistically significant.

### Outcome of meta-analysis

The random-effects model was applied to pooled data as there were distinct definitions of outcome and differing patient baseline characteristics between trials. Results presented in [Fig. 2](#f2-ol-0-0-8070){ref-type="fig"} demonstrate that the pooled DOR was 6.70 (95% CI, 4.59--9.76), heterogeneity χ^2^ =11.99 (P=0.286) and I^2^=16.60%. In the present study, the symmetrical SROC of P-53 was 0.73 ([Fig. 3](#f3-ol-0-0-8070){ref-type="fig"}). Thus, according to results of the present study, s-p53 antibody exhibited reasonable accuracy in terms of differential diagnosis in cases of CRC. The range of the sensitivity was between 13 and 63%, pooled sensitivity was 0.19 (95% CI, 0.18--0.21; [Fig. 5](#f5-ol-0-0-8070){ref-type="fig"}), specificity was between 87 and 100% and pooled specificity was 0.93 (95% CI, 0.92--0.94) ([Figs. 4](#f4-ol-0-0-8070){ref-type="fig"} and [5](#f5-ol-0-0-8070){ref-type="fig"}). In the present study, results demonstrated a pooled PLR of 4.56 (95% CI, 3.27--6.34), suggesting that patients with CRC exhibited 4.56-fold increased chance of testing positive for s-p53 antibody compared with patients without CRC ([Fig. 6](#f6-ol-0-0-8070){ref-type="fig"}). Furthermore, the NLR was 0.78 (95% CI, 0.71--0.85; [Fig. 7](#f7-ol-0-0-8070){ref-type="fig"}). Significant heterogeneity was identified for all eligible studies. Heterogeneity χ^2^ =84.27 (P\<0.001) and I^2^=88.10%.

### Possible sources of heterogeneity

The meta-regression was adopted to explore the possible sources of heterogeneity, which included: Variation in the quality of methodology (QUADAS), study design, sample size, assay method, staging system (stage I %) (TNM) and the time taken to collect and fix the sample. Meta-regression indicated that study design (pre- or post-treatment) \[relative diagnostic odds ratio, 1.68; 95% (0.65--4.36)\] was the probable source of heterogeneity.

### Publication bias evaluation and sensitivity analysis

Despite the studies included in the meta-analysis exhibiting some heterogeneity, the results of the present study demonstrated that no publication bias was detected by using Egger\'s test (P=0.72). Furthermore, the funnel plots ([Fig. 6](#f6-ol-0-0-8070){ref-type="fig"}) used to detect publication bias also demonstrated no asymmetry upon visual inspection. Sensitivity analysis was conducted in terms of statistical analysis methods, study design and sample size. The results of sensitivity analysis produced no obvious changes. When the studies without matched cases and control sample size were excluded, results were not affected.

Discussion
==========

The p53 gene comprises \~20,000 base pairs spread over 11 exons located on 17 p13 ([@b33-ol-0-0-8070]--[@b36-ol-0-0-8070]). Discovered in 1979, it serves a critical function as a tumor-suppressor gene ([@b37-ol-0-0-8070],[@b38-ol-0-0-8070]). As previously established, the s-p53 antibody is not a specific biomarker for CRC ([@b34-ol-0-0-8070],[@b35-ol-0-0-8070]). However, positive associations have been reported between p53 immunoreactivity and the presence of s-p53 antibodies in patients with other types of cancer, including gastric carcinoma ([@b39-ol-0-0-8070]), esophageal carcinoma ([@b40-ol-0-0-8070]) and ovarian carcinoma ([@b41-ol-0-0-8070]). Previous studies on the molecular biology of malignant tumors have emphasized the importance of a number of proto-oncogenes and tumor suppressor genes in human malignancy. Thus, the identification of biomarkers that are capable of providing a definitive diagnosis in various types of malignancy is of high importance in order to provide improved management for patients ([@b11-ol-0-0-8070]).

CRC is one of the most commonly diagnosed cancers globally ([@b17-ol-0-0-8070],[@b33-ol-0-0-8070]). However, early detection of CRC remains challenging in clinical practice. To the best of our knowledge, there is currently no diagnostic biomarker for CRC. Recently, the s-p53 antibody has been widely utilized in clinical practice as a tumor biomarker for CRC; however, results vary between studies and no large-scale studies have been conducted which investigate the use of S-p53Ab as a diagnostic tool for patients with CRC ([@b4-ol-0-0-8070],[@b20-ol-0-0-8070]). The meta-analysis conducted in the present study was used to summarize the potential diagnostic value of s-p53 antibody for the early detection of CRC. The conclusions drawn from the meta-analysis are as follows: i) The pooled sensitivity was 0.19 (95% CI, 0.18--0.21) and the pooled specificity was 0.93 (95% CI, 0.92--0.94); ii) patients with CRC have an increased chance of exhibiting a positive s-p53 test compared with patients without CRC; iii) the odd ratio for positive test for CRC was increased 5-fold compared with the odds ratio for positive test in non CRC. In brief, s-p53-antibody may be useful for the detection and diagnosis of CRC; however, it is important to recognize that s-p53-antibody exhibits low sensitivity levels.

The results of the present study reveal that s-p53 may serve a significant function in screening for cancer, offering a convenient, noninvasive, low costs biomarker with the assumption that future research focuses on the following: i) Improve the sensitivity and specificity by combining additional serum tumor biomarkers; ii) use sputum, serum or other samples that are easy to acquire to improve sensitivity; iii) standardize the detection method and threshold values (lower threshold value leads to increased sensitivity and decreased specificity); iv) conduct normative diagnostic tests or collect samples from cases prior to biopsy in order to improve sensitivity. Collectively, these conditions may decrease the heterogeneity among the included studies, enabling future studies to conduct an accurate meta-analysis to identify the diagnostic value of the s-p53 antibody.

It is important to appreciate the limitations of the present study including: i) Lack of calculation for diagnostic accuracy for early stage (stage I--II) CRC due to lack of access to raw data; additionally, only five studies with small patient cohorts described the different stages of CRC; ii) all 11 included studies lacked the appropriate matching of age, location, and methods of obtaining and handling of the samples between case and control. Furthermore, large-scale studies are required to examine the association between s-p53 antibodies, disease staging and prognosis for patients with CRC. Collectively, this will assist in improving the treatment options for patients with CRC.

In conclusion, according to the results of the present study, s-p53 antibody demonstrated a potential diagnostic value with low sensitivity. Furthermore, patients with CRC have an increased chance of exhibiting a positive result for the p-53 antibody test compared with patients without CRC. Due to its high specificity, s-p53 antibody may be useful for monitoring residual tumor cells and aiding in the diagnosis of patients who have CRC. Larger scale research is required to identify the patterns of multiple biomarkers to further increase the power of CRC detection.
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###### 

Main characteristics and results of the 11 eligible studies.

  Author/year                Country   Ref. standard   Assay method   Cut-off       TP    FP   FN    TN
  -------------------------- --------- --------------- -------------- ------------- ----- ---- ----- -----
  Shimada *et al*, 2003      Japan     Unknown         ELISA          1.3 U/ml      46    23   146   371
  Yoshizawa *et al*, 2007    Japan     Histology       ELISA          mean+2SD      43    44   39    305
  Tagi *et al*, 2010         Japan     Histology       ELISA          Unknown       30    2    100   23
  Hammel *et al*, 1997       France    Histology       ELISA          Unknown       14    0    40    24
  Kojima *et al*, 2009       Japan     Histology       ELISA          6 u/ml        9     0    36    22
  Takeda *et al*, 2001       Japan     Histology       ELISA          Index≥1.1     17    1    10    37
  Lechpammer *et al*, 2003   America   Histology       ELISA          Index≥0 Abs   40    0    180   42
  Broll *et al*, 2001        Germany   Histology       ELISA          Index≥0 Abs   20    0    110   44
  Shiota *et al*, 2000       Japan     Histology       ELISA          Unknown       18    1    53    17
  Wu *et al*, 2011           China     Histology       ELISA          index\>1.7    24    20   52    180
  Tang *et al*, 2001         China     Histology       ELISA          10 u/Ul       130   2    868   209

###### 

Main characteristics of the 11 eligible studies.

  Author, year               Time of specimen collection   Stage I, % (proportion)   QUADAS   Consecutive/random   (Refs.)
  -------------------------- ----------------------------- ------------------------- -------- -------------------- ----------------------
  Shimada *et al*, 2003      Unknown                       Unknown                   6        Unknown              ([@b22-ol-0-0-8070])
  Yoshizawa *et al*, 2007    Unknown                       Unknown                   7        Consecutive          ([@b23-ol-0-0-8070])
  Tagi *et al*, 2010         Unknown                       15% (19/130)              8        Unknown              ([@b24-ol-0-0-8070])
  Hammel *et al*, 1997       Prior to treatment            19% (10/54)               6        Unknown              ([@b30-ol-0-0-8070])
  Kojima *et al*, 2009       Unknown                       36% (16/45)               7        Unknown              ([@b26-ol-0-0-8070])
  Takeda *et al*, 2001       Prior to treatment            Unknown                   8        Consecutive          ([@b27-ol-0-0-8070])
  Lechpammer *et al*, 2003   Prior to treatment            12.7% (28/220)            9        Consecutive          ([@b28-ol-0-0-8070])
  Broll *et al*, 2001        Prior to treatment            32% (41/130)              8        Unknown              ([@b29-ol-0-0-8070])
  Shiota *et al*, 2000       Prior to treatment            Unknown                   8        Consecutive          ([@b25-ol-0-0-8070])
  Wu *et al*, 2011           Prior to treatment            (2/67)                    8        Consecutive          ([@b31-ol-0-0-8070])
  Tang *et al*, 2001         Before treatment              25% (252/998)             7        Consecutive          ([@b32-ol-0-0-8070])

QUADAS, quality assessment of studies of diagnostic accuracy.
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